Reproductive Health and Infertility Department, Guangdong Woman and Children's Hospital, Guangzhou 511442, China.
Reproductive Health and Infertility Department, Guangdong Woman and Children's Hospital, Guangzhou 511442, China.
J Gynecol Obstet Hum Reprod. 2021 Sep;50(7):102110. doi: 10.1016/j.jogoh.2021.102110. Epub 2021 Mar 13.
It remains under subject of debate regarding the optimal route of luteal support for hormone replacement therapy- frozen embryo transfer (HRT-FET) cycles. We compared efficacy of vaginal progesterone gel combined with oral dydrogesterone and intramuscular progesterone for HRT-FET lutein support.
This is a retrospective observational study. After matching for propensity score of getting vaginal + oral treatment, a total of 208 FET cycles in the vaginal progesterone combined with oral dydrogesterone and 624 cycles in the intramuscular progesterone group were enrolled. Pregnancy outcomes and neonatal outcomes including chemical pregnancy rate, clinical pregnancy rate, implantation rate, spontaneous abortion rate, live birth rate, gestational weeks, pre-term delivery, birth weight, and congenital anomalies rate were compared.
No significant differences were observed in patient characteristics such as age, duration of infertility, type of infertility, or hormone level after matching. Chemical pregnancy rate (68.3 % versus 70.5 %), clinical pregnancy rate (64.9 % versus 64.4 %), implantation rate (52.3 % versus 50.2 %), spontaneous abortion rate (21.5 % versus 18.4 %), and live birth rate (49.0 % versus 51.3 %) were similar in both group without statistically significant difference. No significant differences in neonatal outcomes were observed between the two groups.
We observed similar pregnancy outcomes in both vaginal progesterone gel combined with oral dydrogesterone and intramuscular progesterone protocol. Vaginal progesterone gel combined with oral dydrogesterone can be substituted for intramuscular progesterone given that vaginal plus oral use has good safety and is more convenient and may be associated with less side effect caused by intramuscular injection.
关于激素替代疗法-冷冻胚胎移植(HRT-FET)周期黄体支持的最佳途径仍存在争议。我们比较了阴道孕酮凝胶联合口服地屈孕酮和肌肉注射孕酮用于 HRT-FET 黄体支持的疗效。
这是一项回顾性观察性研究。在对获得阴道+口服治疗的倾向评分进行匹配后,共纳入 208 例阴道孕酮联合口服地屈孕酮组和 624 例肌肉注射孕酮组的 FET 周期。比较妊娠结局和新生儿结局,包括化学妊娠率、临床妊娠率、着床率、自然流产率、活产率、妊娠周数、早产、出生体重和先天性异常发生率。
匹配后患者特征如年龄、不孕持续时间、不孕类型或激素水平无显著差异。两组的化学妊娠率(68.3%比 70.5%)、临床妊娠率(64.9%比 64.4%)、着床率(52.3%比 50.2%)、自然流产率(21.5%比 18.4%)和活产率(49.0%比 51.3%)相似,无统计学差异。两组新生儿结局无显著差异。
我们观察到阴道孕酮凝胶联合口服地屈孕酮和肌肉注射孕酮方案的妊娠结局相似。阴道孕酮凝胶联合口服地屈孕酮可替代肌肉注射孕酮,因为阴道加口服使用具有良好的安全性,更方便,可能与肌肉注射引起的副作用较少有关。